Hydrocortisone Acetate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Hydrocortisone Acetate
- Hydrocortisone Acetate: From No Canadian Market Authorization to Alopecia Areata
Using data-report discipline (present exactly what’s in the Evidence Pack, no fabrication, mark data gaps honestly) since this task is generating a report from supplied JSON data — no other skill applies to drafting this document.
Hydrocortisone Acetate: From No Canadian Market Authorization to Alopecia Areata
One-Sentence Summary
Hydrocortisone acetate (DrugBank DB14539) currently has no recorded original indication and is not marketed in Canada in this dataset. The TxGNN model predicts it may be effective for Alopecia Areata, with 1 clinical trial and 2 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication text on file (drug not currently marketed in Canada) |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L2 |
| Canada Market Status | Not marketed |
| Number of DINs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data and original indication information for hydrocortisone acetate are not available in this dataset. Based on known pharmacology, hydrocortisone acetate is a corticosteroid (glucocorticoid receptor agonist) with well-established topical and intralesional anti-inflammatory and immunosuppressive activity, and it is already used in dermatologic practice.
Alopecia areata is a T-cell–mediated autoimmune disease in which immune cells attack hair follicles within their normally immune-privileged niche, producing peribulbar inflammatory infiltration. Corticosteroids such as hydrocortisone suppress local T-cell activity and cytokine release, reducing this perifollicular inflammation — which is why topical/intralesional corticosteroids are already a standard or adjunct treatment option for alopecia areata in clinical dermatology.
Because the drug’s anti-inflammatory mechanism directly addresses the immune-mediated pathology of alopecia areata, and because hydrocortisone has already been evaluated head-to-head against a higher-potency steroid (clobetasol) in this exact condition, the TxGNN prediction is mechanistically plausible even though hydrocortisone-acetate-specific efficacy data remain limited.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01453686 | Phase 3 | Completed | 41 | Randomized controlled trial in children comparing Clobetasol Propionate 0.05% cream vs. Hydrocortisone 1% cream for alopecia areata; hydrocortisone served as the lower-potency active comparator, providing direct clinical data on topical steroid efficacy boundaries in this condition. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 4755919 | 1973 | Case Series | Przeglad dermatologiczny | Reports treatment of severe alopecia areata using intralesional/subcutaneous injections of hydrocortisone acetate suspension. |
| 153470 | 1979 | Review | MMW, Munchener medizinische Wochenschrift | Review of topical corticosteroid therapy in skin disease; references hydrocortisone acetate’s anti-inflammatory potency as a comparator benchmark for newer agents. |
Canada Market Information
Hydrocortisone acetate currently has no recorded market authorization in Canada — no DINs or product licenses are on file in this dataset.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 3 RCT directly compares hydrocortisone to a higher-potency corticosteroid in pediatric alopecia areata, and topical/intralesional corticosteroids are already an established treatment class for this condition — giving the prediction reasonable mechanistic and clinical grounding despite the limited volume of hydrocortisone-acetate-specific trial data.
To proceed, the following is needed:
- Health Canada product monograph warnings/contraindications (currently a Blocking data gap — required before any safety pre-screen can proceed)
- Mechanism of action documentation from DrugBank (currently a High-severity data gap)
- Confirmation of Canadian market authorization status, since the drug is currently listed as not marketed
- Additional hydrocortisone-acetate-specific trials or literature focused on efficacy in alopecia areata (existing evidence is largely a comparator trial and older case reports)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.